Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. (15th March 2018)

• Record Type: Journal Article
• Authors: Pilla Reddy, Venkatesh; Walker, Michael; Sharma, Pradeep; Ballard, Peter; Vishwanathan, Karthick
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 7:Number 5(2018)
• Page Start: 321
• Page End: 330
• Publication Date: 2018-03-15
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12289
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract : Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistance protein (BCRP). A combination of in vitro data, clinical pharmacokinetic data, and drug‐drug interaction (DDI) data of osimertinib in oncology patients were used to develop the physiologically based pharmacokinetic (PBPK) model and verify the DDI data of osimertinib. The model predicted the observed monotherapy concentration profile of osimertinib within 1.1‐fold, and showed good predictability (within 1.7‐fold) to the observed peak plasma concentration (Cmax ) and area under the curve (AUC) DDI ratio changes, when co‐administered with rifampicin, itraconazole, and simvastatin, but not with rosuvastatin. Based on observed clinical data and PBPK simulations, the recommended dose of osimertinib when dosed with strong CYP3A inducers is 160 mg once daily. PBPK modeling suggested no dose adjustment with moderate and weak CYP3A inducers.